NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome | NeurologyLive - Clinical Neurology News and Neurology Expert Insights The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhi...

At #AES2025, Joseph Sullivan, MD reviewed early POLARIS phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy targeting SCN1A in inhibitory interneurons—showing encouraging #seizureReduction & developmental gains in young children.

👉 Read more: www.neurologylive.com/view/neurovo...

Personalized multichannel tDCS reduced seizure frequency by 20% overall; 37% of patients were responders, with one seizure-free case.
doi.org/10.1002/epi4...

#epilepsy #ILAE #epilepsiaopen #brainstimulation #comorbidities #neuromodulation #QOL #seizurereduction #tDCS